OakChart

Cingulate Inc

CINGHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:36 PM ET

4.62+0.06 (1.32%)
2026-11-11 21:37 CET
Market cap
66.31 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-28.81 USD m
Free cash flow, TTM
-20.94 USD m
EPS diluted, TTM
-3.62
P/E
-
Compare

Price

CING against its 20, 50 and 200-day averages
2050200beatmiss
3.004.005.006.002.3M4.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CINGclose 4.6220-day 4.7350-day 4.88200-day 5.404.6252w low

61.1% under the 52-week high of 11.89 on 17 Mar 2026. 52-week low 3.16 on 1 Jun 2026. Last 15 sessions, 34.5% high to low

Volume 1.08× normal · the line is the 50-bar volume average

Profile

CING
52-week range, 17% of the way up
3.1611.89

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Employees14
IPODec 08, 2021
Beta-0.88
ATR, 14d0.30
Rel volume1.08
Short float8.55%
Insider own16.53%
Inst own13.50%

Snapshot

6 groups

Valuation

Index-
Market Cap67.18M
Enterprise Value45.07M
Income-28.81M
Sales0.00M
Book/sh1.69
Cash/sh1.95
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPODec 08, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.74
P/C2.37
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.50
Current Ratio3.50
Debt/Eq0.27
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.62
EPS next Y-1.75
EPS next Q-0.43
EPS this Y51.97%
EPS next Y17.82%
EPS next 5Y35.89%
EPS past 3/5Y77.21% 50.70%
Sales past 3/5Y- -
EPS Y/Y TTM37.29%
Sales Y/Y TTM-
EPS Q/Q59.19%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.28.00% -

Ownership

Insider Own16.53%
Insider Trans4.22%
Inst Own13.50%
Inst Trans3.47%
ROA-123.76%
ROE-198.74%
ROIC-117.85%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.23%
SMA50-5.39%
SMA200-14.52%
Trades-

Technical

Shs Outstand13.89M
Shs Float12.14M
Short Float8.55%
Short Ratio8.67
Short Interest1.04M
52W High11.89 -61.14%
52W Low3.16 46.20%
Volatility6.59% 6.49%
ATR (14)0.30
RSI (14)46.42
Beta-0.88
Rel Volume1.08
Avg Volume119.63K
Volume121,775

Performance

Perf Week1.32%
Perf Month-2.12%
Perf Quarter-7.41%
Perf Half Y-6.10%
Perf YTD6.45%
Perf Year25.89%
Perf 3Y-93.89%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price21.50
Prev Close4.56
Price4.62
Change %1.32%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jan 10, 2025InitiatedRROTH MKMBuy$12+159.7%
Dec 22, 2023DowngradeLLaidlawBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
AYTUAytu BioPharma Inc19.83M
COLLCollegium Pharmaceutical Inc766.97M
ZVRAZevra Therapeutics Inc708.11M
SUPNSupernus Inc6.10B
AXSMAxsome Therapeutics Inc7.81B
NRXPNRX Pharmaceuticals Inc105.85M
TNXPTonix Pharmaceuticals Holding Corp75.51M
VTGNVistagen Therapeutics Inc8.29M
LPCNLipocine Inc17.61M
NBIXNeurocrine Biosciences Inc17.59B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hargroves Thomas JeffreyDirectorFeb 13 '26Buy5.0497,276490,27197,468Jun 08 07:02 PM
Werth Peter J.DirectorFeb 06 '26Buy5.0419,45598,053117,449Feb 10 07:00 PM
Callahan Jennifer L.SVP and CFOFeb 06 '26Buy5.044,86424,5155,059Feb 10 07:00 PM
Schaffer Shane J.Chief Executive OfficerFeb 06 '26Buy5.046,80934,31710,175Feb 10 07:00 PM
Brams MatthewEVP and Chief Medical OfficerFeb 06 '26Buy5.041,9469,8084,656Feb 10 07:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King (GlobeNewswire)
  • Shane Schaffer, Cingulate Chairman & CEO to Present "SMART Launch" Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma (GlobeNewswire)
  • Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness (GlobeNewswire)
  • Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile (GlobeNewswire)
  • Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology (GlobeNewswire) +5.19%
  • Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E (GlobeNewswire) -8.66%
  • Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 (GlobeNewswire)
  • Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 (Newsfile) -6.35%
  • Cingulate Receives Complete Response Letter from FDA for CTx-1301 (GlobeNewswire) +11.94%
  • Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 (GlobeNewswire) -10.77%
  • Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 (Newsfile)
  • Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (GlobeNewswire) -31.05%
  • Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
  • Cingulate price target lowered to $16 from $17 at Roth Capital (TipRanks)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.450-0.625-0.4500.000.006
2026Q12026-05-14-0.950-0.520-0.9540.000.004
2025Q42026-03-18-0.974-0.632-0.8650.000.005
2025Q32025-11-13-1.350-0.880-1.3520.000.004
2025Q22025-08-19-1.038-0.915-1.0910.000.004
2025Q12025-05-08-1.040-1.008-1.0430.000.004
2024Q42025-03-26-1.853-1.375-1.8020.000.004
2024Q32024-11-08-1.830-2.363-1.8300.000.003
2024Q22024-08-13-5.470-5.640-5.4740.000.002
2024Q12024-05-08-7.200-13.980-7.2130.000.002
2023Q42024-04-01-59.100-58.320-71.2760.000.004
2023Q32023-11-13-72.000-88.800-72.5950.000.004
2023Q22023-08-14-136.8-84.800-135.780.000.003
2023Q12023-05-10-84.000-75.600-84.989--2
2022Q42023-03-10-98.400-89.400-97.726-0.004
2022Q32022-11-14-86.400-88.800-85.4640.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-669.6-265.2-439.49-0.00
2022FY-374.4-364.2-375.110.000.00
2023FY-312-333.21-311.990.000.00
2024FY-9.738-9.435-10.8600.000.00
2025FY-4.433-3.820-4.3900.000.00
2026FY--2.133--0.00
2027FY--1.753--12.17
2028FY--1.170--32.96
2029FY--0.410--25.47
2030FY-0.660--44.56

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-113000.000.000.00
2026Q3S2026-09-024000.000.000.00
2026Q3S2026-08-135000.540.002.70
2026Q3S2026-06-025000.540.002.70
2026Q3S2026-05-224000.680.002.70
2026Q3S2026-05-183000.000.000.00
2026Q3S2026-05-142000.000.000.00
2026Q3S2026-04-072000.000.000.00
2026Q3S2026-03-181000.000.000.00
2026Q3S2026-01-283000.170.000.50
2026Q3S2025-12-053010.170.000.50
2026Q3S2025-11-282010.250.000.50
2026Q3S2025-11-143010.170.000.50
2026Q3S2025-11-133000.470.001.40

Estimate history

EPS, annual-131.146-152.446-439.493-375.113-311.988-10.86-4.441-3.6157
Period2019202020212022202320242025TTM
EPS, quarterly-5.474-1.83-1.802-1.043-1.091-1.352-0.865-0.954-0.445
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0880.0470.0470.0470.0973.4027.2513.895
Period2019202020212022202320242025MRQ
Shares, quarterly0.7813.0443.4023.8264.8895.9777.2511.90813.895
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.450.540.650.580.620.810.840.18
Gross Profit-0.45-0.54-0.65-0.58-0.62-0.81-0.84-0.18
Selling, General and Administrative Excl. Other24.4719.4014.9922.1816.8819.876.2411.47
Research and Development8.529.779.4515.499.008.415.099.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-24.92-19.94-15.64-22.76-17.50-20.68-7.08-11.65
Interest Expense-0.920.06--0.030.050.00
Unusual Expense2.591.961.010.000.000.000.000.00
Net Income Before Taxes-28.80-22.45-16.56-23.53-17.68-20.71-7.18-11.55
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-28.80-22.45-16.56-23.53-17.68-20.71-7.18-11.55
Net Income From Continuing Operations-28.80-22.45-16.56-23.53-17.68-20.71-7.18-11.55
Net Income-28.81-22.45-16.56-23.53-17.68-20.71-7.18-11.55
EPS (Recurring)-2.05-4.17-10.39-311.99-375.11-439.49-152.45-131.15
EPS (Basic, Before Extraordinaries)-3.62-4.44-10.86-311.99-375.11-439.49-152.45-131.15
EPS (Diluted)-3.62-4.44-10.86-311.99-375.11-439.49-152.45-131.15
EBITDA-24.47-19.40-14.99-22.18-16.88-19.87-6.24-11.47
Non-Operating Income (Expense)-1.040.370.16-0.78-0.170.00-0.050.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.381.431.000.810.800.04--
Shares Outstanding13.897.253.400.100.050.050.050.09
Market Capitalization66.3166.3115.846.6511.3131.2129.97-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.120.120.110.150.170.160.17
Gross Profit-0.10-0.12-0.12-0.11-0.15-0.17-0.16-0.17
Selling, General and Administrative Excl. Other5.327.805.465.894.503.546.053.12
Research and Development1.492.182.002.852.702.224.331.43
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.41-7.92-5.59-6.00-4.65-3.71-6.21-3.28
Interest Expense0.24-------
Unusual Expense0.471.190.580.360.000.000.000.00
Net Income Before Taxes-5.87-9.31-6.27-7.34-4.79-3.80-6.13-3.23
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.87-9.31-6.27-7.34-4.79-3.80-6.13-3.23
Net Income From Continuing Operations-5.87-9.31-6.27-7.34-4.79-3.80-6.13-3.23
Net Income-5.87-9.32-6.27-7.34-4.79-3.80-6.13-3.23
EPS (Recurring)-0.42-0.87-0.81-1.31-1.09-1.04-1.80-1.83
EPS (Basic, Before Extraordinaries)-0.45-0.95-0.87-1.35-1.09-1.04-1.80-1.83
EPS (Diluted)-0.45-0.95-0.87-1.35-1.09-1.04-1.80-1.83
EBITDA-5.32-7.80-5.46-5.89-4.50-3.54-6.05-3.12
Non-Operating Income (Expense)0.25-0.20-0.10-0.99-0.14-0.100.080.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.360.730.290.000.090.360.180.39
Shares Outstanding13.8911.917.255.984.893.833.403.04
Market Capitalization66.3172.2129.3321.2217.2813.8115.8410.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments10.9512.210.055.3616.491.200.44
Short Term Receivables0.010.030.010.230.690.150.11
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.990.420.332.281.700.440.43
Total Current Assets11.9512.660.407.8718.881.790.98
Net Property, Plant & Equipment3.072.202.913.544.004.004.16
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00-
Other Assets0.060.000.180.000.000.000.14
Total Assets15.0714.863.4911.4122.895.795.28
Short Term Debt Incl. Current Port. of LT Debt6.532.663.385.360.311.170.53
Accounts Payable2.041.275.200.760.260.981.90
Other Current Liabilities1.741.041.650.890.601.220.52
Total Current Liabilities10.314.9710.237.011.183.362.95
Long Term Debt2.252.440.140.510.871.111.71
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.020.00
Total Liabilities12.567.4110.367.522.044.504.66
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity2.517.46-6.873.8820.841.290.62
Total Shareholders Equity2.517.46-6.873.8820.841.290.62
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity2.517.46-6.873.8820.841.290.62
Total Liabilities & Stockholders Equity15.0714.863.4911.4122.895.795.28
Book Value Per Share0.352.19-70.6182.38442.3327.437.00
Tangible Book Value Per Share0.352.19-70.6182.38442.3327.437.00
Full-Time Employees1413131516--
Price to Book Ratio2.701.25-69.001.35---
Return on Assets-149.98-180.43-315.98-103.09-144.45-129.80-
Return on Equity-450.60-5,651.01--142.98-187.12-752.88-
Return on Invested Capital-471.57-167.40--402.44-95.40-299.01-495.65
Quick Ratio1.162.550.041.1216.050.530.33
Current Ratio1.162.550.041.1216.050.530.33

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-29.04-22.45-16.56-23.53-17.68-20.71-7.18-11.55
Depreciation0.450.540.650.580.620.810.840.18
Other Funds (Non Cash)5.973.832.010.810.8012.780.00-0.05
Funds from Operations-22.62-18.08-13.90-22.14-16.25-7.12-6.34-11.42
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital1.970.83-4.557.100.37-3.31-0.472.61
Cash from Operating Activities-20.65-17.25-18.45-15.03-15.88-10.43-6.81-8.81
Capital Expenditures-0.28-0.16-0.21-0.22-0.15-0.81-0.40-1.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.023.76
Purchase of Investments0.000.000.000.000.000.00-0.00-1.55
Sale Or Maturity of Investments0.000.000.000.000.000.000.025.31
Other Uses0.000.000.000.00-0.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.28-0.16-0.21-0.22-0.15-0.81-0.382.74
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock35.1010.1525.886.97-0.0927.487.510.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock35.1010.1525.886.97-0.0927.487.510.00
Proceedsfrom Stock Options35.1010.1525.886.97-0.0927.487.510.00
Issuance or Reduction of Debt, Net0.006.004.953.005.00-0.500.85-0.73
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.006.14
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities40.4416.1530.829.954.9026.547.975.42
Net Change in Cash19.50-1.2612.16-5.30-11.1415.300.78-0.64
Free Cash Flow-20.94-17.41-18.66-15.26-16.04-11.25-7.21-9.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments28.4025.8910.956.128.909.52
Short Term Receivables0.040.050.010.020.020.04
Inventories0.000.000.000.000.000.00
Other Current Assets1.771.970.991.301.300.94
Total Current Assets30.2127.9111.957.4310.2210.50
Net Property, Plant & Equipment2.862.953.073.093.251.96
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.060.000.000.00
Total Assets33.0730.8615.0710.5213.4712.47
Short Term Debt Incl. Current Port. of LT Debt5.326.396.533.425.364.16
Accounts Payable1.992.672.040.870.870.86
Other Current Liabilities1.321.901.741.600.500.60
Total Current Liabilities8.6310.9610.315.886.735.62
Long Term Debt0.971.042.251.161.220.92
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities9.6012.0012.567.057.966.54
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity23.4718.862.513.475.515.93
Total Shareholders Equity23.4718.862.513.475.515.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity23.4718.862.513.475.515.93
Total Liabilities & Stockholders Equity33.0730.8615.0710.5213.4712.47
Book Value Per Share1.691.580.350.581.131.55
Tangible Book Value Per Share1.691.580.350.581.131.55
Full-Time Employees--14---
Price to Book Ratio2.7017.957.473.482.631.96
Return on Assets-123.76-127.92-148.34-183.12-193.12-182.32
Return on Equity-198.74-223.55-445.69-284.50-417.77-358.06
Return on Invested Capital-24.02-46.79-131.77-158.33-71.10-55.48
Quick Ratio3.502.551.161.261.521.87
Current Ratio3.502.551.161.261.521.87

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.87-9.31-6.27-7.59-4.79-3.80
Depreciation0.100.120.120.110.150.17
Other Funds (Non Cash)0.921.940.982.130.270.44
Funds from Operations-4.86-7.25-5.17-5.34-4.37-3.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.040.341.571.10-0.43-1.41
Cash from Operating Activities-5.90-6.91-3.60-4.24-4.80-4.61
Capital Expenditures-0.07-0.06-0.160.00-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.07-0.06-0.160.00-0.010.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock9.1421.912.591.464.181.92
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.1421.912.591.464.181.92
Proceedsfrom Stock Options9.1421.912.591.464.181.92
Issuance or Reduction of Debt, Net-0.660.006.000.000.00-0.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.4821.918.591.464.181.92
Net Change in Cash2.5114.944.83-2.78-0.62-2.69
Free Cash Flow-5.97-6.97-3.75-4.24-4.80-4.61

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.55%1.0M12.1M121.13K
2026-10-158.38%1.0M12.1M125.86K
2026-09-308.50%1.0M12.1M167.99K
2026-09-159.64%1.2M12.1M214.29K
2026-08-318.83%1.1M12.0M360.91K
2026-08-1410.07%1.2M12.0M437.67K
2026-07-3114.18%1.6M11.1M483.80K
2026-07-1515.16%1.7M11.1M553.84K
2026-06-3012.47%1.4M11.0M556.85K
2026-06-1515.97%1.8M11.0M652.51K
2026-05-2918.09%2.0M10.8M564.79K
2026-05-1514.88%1.6M10.6M519.27K
2026-04-3015.29%1.5M9.8M514.02K
2026-04-1514.53%1.4M9.8M493.05K
2026-03-3113.20%1.1M8.2M473.33K
2026-03-136.38%0.5M8.2M320.63K
2026-02-278.53%0.5M5.4M268.58K
2026-02-137.61%0.4M5.4M238.30K
2026-01-305.32%0.4M7.3M197.45K
2026-01-153.69%0.3M7.3M177.44K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.104.901.900.0009.000.000.949-0.0120.001
call5.000.000.850.303.5891,5490.000.575-0.0660.003
call7.500.000.500.054.0703740.000.341-0.0570.003
call10.000.001.151.055.27776.000.000.300-0.0750.003
call12.500.000.200.055.81978.000.000.281-0.0750.003
put2.500.000.050.032.5951,3610.00-0.052-0.0100.001
put5.000.004.900.7029.9106190.00-0.311-0.1030.003
put7.500.605.504.1011.8250.000.00-0.659-0.0610.003
put10.003.008.006.4012.8361.000.00-0.697-0.0720.002
put12.505.5010.4010.0013.1790.000.00-0.844-0.0420.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-028-KCurrent report2026-09-30SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-238-KCurrent report2026-07-17SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-15S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-148-KCurrent report2026-07-09SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-06-084Statement of changes in beneficial ownership of securities2026-02-13SEC
2026-06-083Initial statement of beneficial ownership of securities2026-02-13SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-29ARSAnnual report to security holders. 2025-12-31SEC
2026-05-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-29SEC
2026-05-198-KCurrent report2026-05-18SEC
2026-05-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-18SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-02656.96K500
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.24%
RAYMOND JAMES FINANCIAL INC1.24%
Kestra Advisory Services, LLC1.08%
GEODE CAPITAL MANAGEMENT, LLC1.05%
RENAISSANCE TECHNOLOGIES LLC0.95%
Chicago Partners Investment Group LLC0.76%
North Star Investment Management Corp.0.69%
VANGUARD FIDUCIARY TRUST CO0.59%
SIMPLEX TRADING, LLC0.49%
UBS Group AG0.47%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.93%
VANGUARD EXTENDED MARKET INDEX FUND1.19%
Fidelity Extended Market Index Fund0.49%
iShares Micro-Cap ETF0.21%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.15%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.08%
Fidelity Nasdaq Composite Index Fund0.06%
VANGUARD BALANCED INDEX FUND0.04%
1290 VT Micro Cap Portfolio0.01%

OakChart. CING. Cached 15 minutes.